Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

A novel locus of resistance to severe malaria in a region of ancient balancing selection

Nature volume 526, pages 253–257 (2015)Cite this article

Subjects

Abstract

The high prevalence of sickle haemoglobin in Africa shows that malaria has been a major force for human evolutionary selection, but surprisingly few other polymorphisms have been proven to confer resistance to malaria in large epidemiological studies1,2,3. To address this problem, we conducted a multi-centre genome-wide association study (GWAS) of life-threatening Plasmodium falciparum infection (severe malaria) in over 11,000 African children, with replication data in a further 14,000 individuals. Here we report a novel malaria resistance locus close to a cluster of genes encoding glycophorins that are receptors for erythrocyte invasion by P. falciparum. We identify a haplotype at this locus that provides 33% protection against severe malaria (odds ratio = 0.67, 95% confidence interval = 0.60–0.76, P value = 9.5 × 10−11) and is linked to polymorphisms that have previously been shown to have features of ancient balancing selection, on the basis of haplotype sharing between humans and chimpanzees4. Taken together with previous observations on the malaria-protective role of blood group O1,2,3,5, these data reveal that two of the strongest GWAS signals for severe malaria lie in or close to genes encoding the glycosylated surface coat of the erythrocyte cell membrane, both within regions of the genome where it appears that evolution has maintained diversity for millions of years. These findings provide new insights into the host–parasite interactions that are critical in determining the outcome of malaria infection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Signal of association with severe malaria across the FREM3/GYPE region.
Figure 2: Evidence for association at SNPs in the FREM3/GYPE region, assuming an additive model of association.
Figure 3: Haplotype analysis across the FREM3/GYPE region.

Similar content being viewed by others

Accession codes

Data deposits

Genotype and phenotype data underlying this manuscript have been deposited in the European Genome-phenome Archive under accession number EGAS00001001311. Access to individual-level genotype data is available by application to an Independent Data Access Committee: see http://www.malariagen.net/data. For further details of data underlying this manuscript, see http://www.malariagen.net/resource/14.

References

  1. Malaria Genomic Epidemiology Network. Reappraisal of known malaria resistance loci in a large multicenter study. Nature Genet. 46, 1197–1204 (2014)

  2. Timmann, C. et al. Genome-wide association study indicates two novel resistance loci for severe malaria. Nature 489, 443–446 (2012)

    Article  ADS  CAS  Google Scholar 

  3. Band, G. et al. Imputation-based meta-analysis of severe malaria in three African populations. PLoS Genet. 9, e1003509 (2013)

    Article  CAS  Google Scholar 

  4. Leffler, E. M. et al. Multiple instances of ancient balancing selection shared between humans and chimpanzees. Science 339, 1578–1582 (2013)

    Article  ADS  CAS  Google Scholar 

  5. Fry, A. E. et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum. Mol. Genet. 17, 567–576 (2008)

    Article  CAS  Google Scholar 

  6. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012)

  7. Teo, Y. Y., Small, K. S. & Kwiatkowski, D. P. Methodological challenges of genome-wide association analysis in Africa. Nature Rev. Genet. 11, 149–160 (2010)

    Article  CAS  Google Scholar 

  8. Manske, M. et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487, 375–379 (2012)

    Article  ADS  CAS  Google Scholar 

  9. Jallow, M. et al. Genome-wide and fine-resolution association analysis of malaria in West Africa. Nature Genet. 41, 657–665 (2009)

    Article  CAS  Google Scholar 

  10. Blumenfeld, O. O. & Huang, C. H. Molecular genetics of the glycophorin gene family, the antigens for MNSs blood groups: multiple gene rearrangements and modulation of splice site usage result in extensive diversification. Hum. Mutat. 6, 199–209 (1995)

    Article  CAS  Google Scholar 

  11. Sim, B. K., Chitnis, C. E., Wasniowska, K., Hadley, T. J. & Miller, L. H. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264, 1941–1944 (1994)

    Article  ADS  CAS  Google Scholar 

  12. Mayer, D. C. et al. Glycophorin B is the erythrocyte receptor of Plasmodium falciparum erythrocyte-binding ligand, EBL-1. Proc. Natl Acad. Sci. USA 106, 5348–5352 (2009)

    Article  ADS  CAS  Google Scholar 

  13. Baum, J., Ward, R. H. & Conway, D. J. Natural selection on the erythrocyte surface. Mol. Biol. Evol. 19, 223–229 (2002)

    Article  CAS  Google Scholar 

  14. Ko, W. Y. et al. Effects of natural selection and gene conversion on the evolution of human glycophorins coding for MNS blood polymorphisms in malaria-endemic African populations. Am. J. Hum. Genet. 88, 741–754 (2011)

    Article  CAS  Google Scholar 

  15. Tarazona-Santos, E. et al. Population genetics of GYPB and association study between GYPB*S/s polymorphism and susceptibility to P. falciparum infection in the Brazilian Amazon. PLoS ONE 6, e16123 (2011)

    Article  ADS  CAS  Google Scholar 

  16. Wang, H. Y., Tang, H., Shen, C. K. & Wu, C. I. Rapidly evolving genes in human. I. The glycophorins and their possible role in evading malaria parasites. Mol. Biol. Evol. 20, 1795–1804 (2003)

    Article  CAS  Google Scholar 

  17. Stranger, B. E. et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 8, e1002639 (2012)

    Article  CAS  Google Scholar 

  18. Gurdasani, D. et al. The African Genome Variation Project shapes medical genetics in Africa. Nature 517, 327–332 (2015)

    Article  ADS  CAS  Google Scholar 

  19. Lanzillotti, R. & Coetzer, T. L. The 10 kDa domain of human erythrocyte protein 4.1 binds the Plasmodium falciparum EBA-181 protein. Malar. J. 5, 100 (2006)

    Article  Google Scholar 

  20. Ségurel, L. et al. The ABO blood group is a trans-species polymorphism in primates. Proc. Natl Acad. Sci. USA 109, 18493–18498 (2012)

    Article  ADS  Google Scholar 

  21. Su, Z., Cardin, N., The Wellcome Trust Case Control Consortium, P. & Marchini, J. A Bayesian method for detecting and characterizing allelic heterogeneity and boosting signals in genome-wide association studies. Stat. Sci. 24, 430–450 (2009)

    Article  MathSciNet  Google Scholar 

  22. Lee, P. H., O’Dushlaine, C., Thomas, B. & Purcell, S. M. INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics 28, 1797–1799 (2012)

    Article  CAS  Google Scholar 

  23. Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious disease in human populations. Nature Rev. Genet. 15, 379–393 (2014)

    Article  CAS  Google Scholar 

  24. Otto, T. D. et al. Genome sequencing of chimpanzee malaria parasites reveals possible pathways of adaptation to human hosts. Nature Commun. 5, 4754 (2014)

    Article  ADS  CAS  Google Scholar 

  25. Liu, W. et al. Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature 467, 420–425 (2010)

    Article  ADS  CAS  Google Scholar 

  26. Prugnolle, F. et al. A fresh look at the origin of Plasmodium falciparum, the most malignant malaria agent. PLoS Pathog. 7, e1001283 (2011)

    Article  CAS  Google Scholar 

  27. Rich, S. M. et al. The origin of malignant malaria. Proc. Natl Acad. Sci. USA 106, 14902–14907 (2009)

    Article  ADS  CAS  Google Scholar 

  28. Joy, D. A. et al. Early origin and recent expansion of Plasmodium falciparum. Science 300, 318–321 (2003)

    Article  ADS  CAS  Google Scholar 

  29. Gilbert, S. C. et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279, 1173–1177 (1998)

    Article  ADS  CAS  Google Scholar 

  30. Binks, R. H. et al. Population genetic analysis of the Plasmodium falciparum erythrocyte binding antigen-175 (eba-175) gene. Mol. Biochem. Parasitol. 114, 63–70 (2001)

    Article  CAS  Google Scholar 

  31. World Health Organization Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94 (suppl. 1), S1–S90 (2000)

    Article  Google Scholar 

  32. Teo, Y. Y. Genotype calling for the Illumina platform. Methods Mol. Biol. 850, 525–538 (2012)

    Article  Google Scholar 

  33. Giannoulatou, E., Yau, C., Colella, S., Ragoussis, J. & Holmes, C. C. GenoSNP: a variational Bayes within-sample SNP genotyping algorithm that does not require a reference population. Bioinformatics 24, 2209–2214 (2008)

    Article  CAS  Google Scholar 

  34. Kent, W. J. BLAT—the BLAST-like alignment tool. Genome Res. 12, 656–664 (2002)

    Article  CAS  Google Scholar 

  35. Bellenguez, C. et al. A robust clustering algorithm for identifying problematic samples in genome-wide association studies. Bioinformatics 28, 134–135 (2012)

    Article  CAS  Google Scholar 

  36. Astle, W. & Balding, D. J. Population structure and cryptic relatedness in genetic association studies. Stat. Sci. 24, 451–471 (2009)

    Article  MathSciNet  Google Scholar 

  37. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007)

  38. R Development Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2015)

  39. Ross, M. T. et al. The DNA sequence of the human X chromosome. Nature 434, 325–337 (2005)

    Article  ADS  CAS  Google Scholar 

  40. Delaneau, O., Zagury, J. F. & Marchini, J. Improved whole-chromosome phasing for disease and population genetic studies. Nature Methods 10, 5–6 (2013)

    Article  CAS  Google Scholar 

  41. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nature Genet. 44, 955–959 (2012)

    Article  CAS  Google Scholar 

  42. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009)

    Article  Google Scholar 

  43. Wakefield, J. Bayes factors for genome-wide association studies: comparison with P-values. Genet. Epidemiol. 33, 79–86 (2009)

    Article  Google Scholar 

  44. Carrel, L., Cottle, A. A., Goglin, K. C. & Willard, H. F. A first-generation X-inactivation profile of the human X chromosome. Proc. Natl Acad. Sci. USA 96, 14440–14444 (1999)

    Article  ADS  CAS  Google Scholar 

  45. Pirinen, M., Donnelly, P. & Spencer, C. C. A. Efficient computation with a linear mixed model on large-scale data sets with applications to genetic studies. Ann. Appl. Stat. 7, 369–390 (2013)

    Article  MathSciNet  Google Scholar 

  46. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348, 648–660 (2015)

  47. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001–D1006 (2014)

    Article  CAS  Google Scholar 

  48. Karolchik, D. et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32, D493–D496 (2004)

    Article  CAS  Google Scholar 

  49. Manjurano, A. et al. USP38, FREM3, SDC1, DDC, and LOC727982 gene polymorphisms and differential susceptibility to severe malaria in Tanzania. J. Infect. Dis. 212, 1129–1139 (2015)

    Article  CAS  Google Scholar 

  50. The Wellcome Trust Case Control Consortium et al. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nature Genet. 44, 1294–1301 (2012)

  51. Hillier, L. W. et al. Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature 434, 724–731 (2005)

    Article  ADS  CAS  Google Scholar 

  52. Zeller, T. et al. Genetics and beyond—the transcriptome of human monocytes and disease susceptibility. PLoS One 5, e10693 (2010)

    Article  ADS  Google Scholar 

Download references

Acknowledgements

The Malaria Genomic Epidemiology Network Project is supported by the Wellcome Trust (WT077383/Z/05/Z) and the Bill & Melinda Gates Foundation through the Foundations of the National Institutes of Health (NIH; 566) as part of the Grand Challenges in Global Health Initiative. The Resource Centre for Genomic Epidemiology of Malaria is supported by the Wellcome Trust (090770/Z/09/Z). This research was supported by the Medical Research Council (MRC; G0600718; G0600230), the Wellcome Trust Biomedical ethics Enhancement Award (087285) and Strategic Award (096527). D.P.K. receives support from the MRC (G19/9). C.C.A.S. was supported by a Wellcome Trust Career Development Fellowship (097364/Z/11/Z). The Wellcome Trust also provides core awards to The Wellcome Trust Centre for Human Genetics (075491/Z/04; 090532/Z/09/Z) and the Wellcome Trust Sanger Institute (077012/Z/05/Z and 098051). The Mali MRTC–BMP group is supported by a contract (N01AI85346) and a cooperative agreement (U19AI065683) from the National Institute of Allergy and Infectious Diseases (NIAID) and by a grant (D43TW001589) from the Fogarty International Centre, NIH to University of Maryland and University of Bamako and the Mali-NIAID/NIH International Center for Excellence in Research at the University of Sciences, Techniques, and Technology of Bamako. E.A. received partial funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 242095–EVIMalaR and the Central African Network for Tuberculosis, HIV/AIDS and Malaria (CANTAM) funded by the European and Developing Countries Clinical Trials Partnership (EDCTP). T.N.W. is funded by Senior Fellowships from the Wellcome Trust (076934/Z/05/Z and 091758/Z/10/Z) and through the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 242095–EVIMalaR. The KEMRI-Wellcome Trust Programme is funded through core support from the Wellcome Trust. C.M.N. is supported through a strategic award to the KEMRI-Wellcome Trust Programme by the Wellcome Trust (084538). Tanzania/Kilimanjaro Christian Medical College Joint Malaria Programme, Moshi, Tanzania received funding from MRC grant number G9901439. We acknowledge the work of B. Poudiougou and A. Niangaly for their help in collecting clinical data and biological samples for the Bamako study. We thank L. Jostins and M. Pirinen for advice on statistical analyses.

Author information

Author notes

  1. Gavin Band, Gavin Band, Kirk A. Rockett, Chris C. A. Spencer, Dominic P. Kwiatkowski, Gavin Band, Gavin Band, Quang Si Le, Geraldine M. Clarke, Katja Kivinen, Ellen M. Leffler, Kirk A. Rockett, Dominic P. Kwiatkowski, Chris C. A. Spencer, Kirk A. Rockett, Kirk A. Rockett, Chris C. A. Spencer, Victoria Cornelius, David J. Conway, Thomas N. Williams, Terrie Taylor, Dominic P. Kwiatkowski, David J. Conway, David J. Conway, Kalifa A. Bojang, Ogobara Doumbo, Mahamadou A. Thera, David Modiano, Sodiomon B. Sirima, Michael D. Wilson, Kwadwo A. Koram, Tsiri Agbenyega, Eric Achidi, Thomas N. Williams, Kevin Marsh, Hugh Reyburn, Chris Drakeley, Eleanor Riley, Terrie Taylor, Malcolm Molyneux, Muminatou Jallow, Muminatou Jallow, Kalifa A. Bojang, David J. Conway, Margaret Pinder, Ogobara Doumbo, Mahamadou A. Thera, Ousmane B. Toure, Salimata Konate, Sibiri Sissoko, Edith C. Bougouma, Valentina D. Mangano, David Modiano, Sodiomon B. Sirima, Lucas N. Amenga-Etego, Anita K. Ghansah, Abraham V. O. Hodgson, Kwadwo A. Koram, Michael D. Wilson, Tsiri Agbenyega, Daniel Ansong, Anthony Enimil, Jennifer Evans, Eric Achidi, Tobias O. Apinjoh, Alexander Macharia, Kevin Marsh, Carolyne M. Ndila, Charles Newton, Norbert Peshu, Sophie Uyoga, Thomas N. Williams, Chris Drakeley, Alphaxard Manjurano, Hugh Reyburn, Eleanor Riley, David Kachala, Malcolm Molyneux, Vysaul Nyirongo, Terrie Taylor, Kirk A. Rockett, Kirk A. Rockett, Katja Kivinen, Daniel Mead, Eleanor Drury, Sarah Auburn, Susana G. Campino, Bronwyn MacInnis, Jim Stalker, Emma Gray, Christina Hubbart, Anna E. Jeffreys, Kate Rowlands, Alieu Mendy, Rachel Craik, Kathryn Fitzpatrick, Sile Molloy, Lee Hart, Robert Hutton, Angeliki Kerasidou, Kimberly J. Johnson and Victoria Cornelius: Lists of participants and their affiliations appear at the end of the paper.

Authors and Affiliations

  1. Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK

    Gavin Band, Kirk A. Rockett, Chris C. A. Spencer, Dominic P. Kwiatkowski, Gavin Band, Quang Si Le, Geraldine M. Clarke, Ellen M. Leffler, Kirk A. Rockett, Dominic P. Kwiatkowski, Chris C. A. Spencer, Kirk A. Rockett, Chris C. A. Spencer, Victoria Cornelius, Dominic P. Kwiatkowski, Kirk A. Rockett, Sarah Auburn, Christina Hubbart, Anna E. Jeffreys, Kate Rowlands, Alieu Mendy, Rachel Craik, Kathryn Fitzpatrick, Sile Molloy, Lee Hart, Robert Hutton, Angeliki Kerasidou, Kimberly J. Johnson & Victoria Cornelius

  2. The Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, Cambridge, UK

    Kirk A. Rockett, Dominic P. Kwiatkowski, Katja Kivinen, Kirk A. Rockett, Dominic P. Kwiatkowski, Kirk A. Rockett, Dominic P. Kwiatkowski, Kirk A. Rockett, Katja Kivinen, Daniel Mead, Eleanor Drury, Susana G. Campino, Bronwyn MacInnis, Jim Stalker & Emma Gray

  3. Medical Research Council Unit, Atlantic Boulevard, PO Box 273, Fajara, The Gambia

    David J. Conway, David J. Conway, Kalifa A. Bojang, Muminatou Jallow, Kalifa A. Bojang, David J. Conway & Margaret Pinder

  4. Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK

    David J. Conway, David J. Conway & David J. Conway

  5. KEMRI-Wellcome Trust Research Programme CGMRC, PO Box 230-80108, Kilifi, Kenya

    Thomas N. Williams, Thomas N. Williams, Kevin Marsh, Alexander Macharia, Kevin Marsh, Carolyne M. Ndila, Charles Newton, Norbert Peshu, Sophie Uyoga & Thomas N. Williams

  6. Department of Medicine, Faculty of Medicine, Imperial College, Exhibition Road, London, SW7 2AZ, UK

    Thomas N. Williams, Thomas N. Williams & Thomas N. Williams

  7. Blantyre Malaria Project, Queen Elizabeth Central Hospital, College of Medicine, P.O. Box 30096, Chichiri, Blantyre 3, Malawi

    Terrie Taylor, Terrie Taylor & Terrie Taylor

  8. College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, 48824, USA

    Terrie Taylor, Terrie Taylor & Terrie Taylor

  9. Malaria Research and Training Centre, Faculty of Medicine University of Bamako, Bamako, Mali

    Ogobara Doumbo, Mahamadou A. Thera, Ogobara Doumbo, Mahamadou A. Thera, Ousmane B. Toure, Salimata Konate & Sibiri Sissoko

  10. University of Rome La Sapienza, Piazzale AldoMoro 5, Rome, 00185, Italy

    David Modiano, Valentina D. Mangano & David Modiano

  11. Centre National de Recherche et de Formation sur le Paludisme (CNRFP), 01 BP 2208 Ouagadougou 01, Burkina, Faso

    Sodiomon B. Sirima, Edith C. Bougouma & Sodiomon B. Sirima

  12. Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 25, Legon, Accra, Ghana

    Michael D. Wilson, Kwadwo A. Koram, Anita K. Ghansah, Kwadwo A. Koram & Michael D. Wilson

  13. Komfo Anokye Teaching Hospital, PO Box 1934, Kumasi, Ghana

    Tsiri Agbenyega, Tsiri Agbenyega, Daniel Ansong & Anthony Enimil

  14. Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

    Tsiri Agbenyega, Tsiri Agbenyega & Daniel Ansong

  15. Department of Medical Laboratory Sciences, University of Buea, P.O. Box 63, Buea, South West Region, Cameroon

    Eric Achidi & Eric Achidi

  16. Joint Malaria Programme, Kilimanjaro Christian Medical Centre, PO box 2228, Moshi, Tanzania

    Hugh Reyburn, Chris Drakeley, Chris Drakeley, Alphaxard Manjurano & Hugh Reyburn

  17. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK

    Hugh Reyburn, Chris Drakeley, Eleanor Riley, Chris Drakeley, Alphaxard Manjurano, Hugh Reyburn & Eleanor Riley

  18. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital, College of Medicine, P.O. Box 30096, Chichiri, Blantyre 3, Malawi,

    Malcolm Molyneux, David Kachala, Malcolm Molyneux & Vysaul Nyirongo

  19. Royal Victoria Teaching Hospital, Independence Drive, PO Box 1515, Banjul, The Gambia

    Muminatou Jallow

  20. Navrongo Health Research Centre, PO Box 114, Navrongo, Ghana

    Lucas N. Amenga-Etego & Abraham V. O. Hodgson

  21. Department of Molecular Medicine, Bernhard Nocht Institute for Tropical Medicine, Postfach 30 41 2, D-20324, Hamburg, Germany

    Jennifer Evans

  22. Kumasi Centre for Collaborative Research, School of Medical Sciences, KNUST, Kumasi, Ghana

    Jennifer Evans

  23. Department of Biochemistry & Molecular Biology, University of Buea, P.O. Box 63 Buea, South West Region, Cameroon

    Tobias O. Apinjoh

  24. Nuffield Department of Population Health, The Ethox Centre, University of Oxford, Old Road Campus, OX3 7LF, Oxford, UK

    Angeliki Kerasidou

Consortia

Malaria Genomic Epidemiology Network

  • Writing group

    • Gavin Band
    • , Kirk A. Rockett
    • , Chris C. A. Spencer
    •  & Dominic P. Kwiatkowski

  • Data analysis

    • Gavin Band
    • , Quang Si Le
    • , Geraldine M. Clarke
    • , Katja Kivinen
    • , Ellen M. Leffler
    • , Kirk A. Rockett
    • , Dominic P. Kwiatkowski
    •  & Chris C. A. Spencer

  • Project management

    • Kirk A. Rockett
    • , Chris C. A. Spencer
    • , Victoria Cornelius
    • , David J. Conway
    • , Thomas N. Williams
    • , Terrie Taylor
    •  & Dominic P. Kwiatkowski

  • Study site lead investigators

    • David J. Conway
    • , Kalifa A. Bojang
    • , Ogobara Doumbo
    • , Mahamadou A. Thera
    • , David Modiano
    • , Sodiomon B. Sirima
    • , Michael D. Wilson
    • , Kwadwo A. Koram
    • , Tsiri Agbenyega
    • , Eric Achidi
    • , Thomas N. Williams
    • , Kevin Marsh
    • , Hugh Reyburn
    • , Chris Drakeley
    • , Eleanor Riley
    • , Terrie Taylor
    •  & Malcolm Molyneux

  • Clinical data and sample collection

    • Muminatou Jallow
    • , Kalifa A. Bojang
    • , David J. Conway
    • , Margaret Pinder
    • , Ogobara Doumbo
    • , Mahamadou A. Thera
    • , Ousmane B. Toure
    • , Salimata Konate
    • , Sibiri Sissoko
    • , Edith C. Bougouma
    • , Valentina D. Mangano
    • , David Modiano
    • , Sodiomon B. Sirima
    • , Lucas N. Amenga-Etego
    • , Anita K. Ghansah
    • , Abraham V. O. Hodgson
    • , Kwadwo A. Koram
    • , Michael D. Wilson
    • , Tsiri Agbenyega
    • , Daniel Ansong
    • , Anthony Enimil
    • , Jennifer Evans
    • , Eric Achidi
    • , Tobias O. Apinjoh
    • , Alexander Macharia
    • , Kevin Marsh
    • , Carolyne M. Ndila
    • , Charles Newton
    • , Norbert Peshu
    • , Sophie Uyoga
    • , Thomas N. Williams
    • , Chris Drakeley
    • , Alphaxard Manjurano
    • , Hugh Reyburn
    • , Eleanor Riley
    • , David Kachala
    • , Malcolm Molyneux
    • , Vysaul Nyirongo
    •  & Terrie Taylor

  • Sample processing, genotyping, data management and project coordination

    • Kirk A. Rockett
    • , Katja Kivinen
    • , Daniel Mead
    • , Eleanor Drury
    • , Sarah Auburn
    • , Susana G. Campino
    • , Bronwyn MacInnis
    • , Jim Stalker
    • , Emma Gray
    • , Christina Hubbart
    • , Anna E. Jeffreys
    • , Kate Rowlands
    • , Alieu Mendy
    • , Rachel Craik
    • , Kathryn Fitzpatrick
    • , Sile Molloy
    • , Lee Hart
    • , Robert Hutton
    • , Angeliki Kerasidou
    • , Kimberly J. Johnson
    •  & Victoria Cornelius

Contributions

Details of author contributions are provided in the author list.

Corresponding authors

Correspondence to Chris C. A. Spencer, Dominic P. Kwiatkowski, Dominic P. Kwiatkowski, Chris C. A. Spencer, Chris C. A. Spencer or Dominic P. Kwiatkowski.

Ethics declarations

Competing interests

The author declare no competing financial interests.

Extended data figures and tables

Extended Data Figure 1 Sample collections included in the study.

a, Study sites and ethics approving institutions. b, Phenotypic makeup of discovery and replication samples from each site. ‘Uncomplicated’ refers to case individuals who were not identified as cerebral malaria (CM) or severe malarial anaemia (SMA) cases. ‘Both’ refers to individuals who have both CM and SMA phenotypes. c, Overall sample counts and number of samples excluded by each quality control (QC) criterion. Asterisk denotes the number of samples removed after explicitly including samples with low heterozygosity in Gambia. Dagger: the Kenyan cohort included parents of a subset of case samples; these were not used in subsequent analyses d–f, Plots of average genome-wide heterozygosity and missingness with outliers coloured, as outputted by the ABERRANT algorithm.

Extended Data Figure 2 Genotyped SNP quality control for the three discovery cohorts.

a, b, Total numbers of pre- and post-quality control SNPs on the autosomes (a) and the X chromosome (b), and numbers of SNPs excluded by each quality control (QC) criterion. Diff, the test of difference in frequency between males and females; HWE, Hardy–Weinberg equilibrium; Plate, plate test of association. Details of quality control are given in Methods. c, Plot showing the –log10(P values) for the genotypic association test in the discovery data including the first five principal components as covariates. Grey dots show SNPs that are removed due to the quality control as defined in Methods. The total fraction of SNPs removed from each cohort is given at the top of the plot.

Extended Data Figure 3 Imputation performance.

a, b, Empirical distribution of concordance and accuracy (r2) between typed and re-imputed SNPs in the three discovery cohorts. Solid lines represent SNPs with frequency below 5% and dashed lines represent SNPs with frequency of at least 5%. c, Per-sample concordance and accuracy (type 0 r2) across the whole genome, as estimated by re-imputing genotyped SNPs. Values are averaged over imputation chunks. d, Average accuracy between genotype and re-imputed SNPs in each cohort, plotted against frequency, in 1% frequency bins.

Extended Data Figure 4 Detail of population structure.

a–c, Top ten principal components (PCs) in Gambia (a), Malawi (b) and Kenya (c). Where ethnicity was reported, points are coloured by ethnicity for ethnicities with at least 50 samples. d, Logistic regression P values and direction of effect for the top ten PCs on severe malaria status in each cohort. e, q–q plots for additive model association test P values in Gambia, Malawi, Kenya, and for fixed-effect meta-analysis. Dashed lines represent the 99% CI computed marginally at each variant. Circles and points represent points lying respectively outside and inside the 99% CI. f, Comparison of association test P values for logistic regression (SNPTEST, x-axis) and linear mixed model (MMM, y-axis) for Gambia, Malawi, Kenya, and for fixed-effect meta-analysis. Variants in tier 1 are coloured blue, with the lead marker at the FREM3/GYPE region coloured red.

Extended Data Figure 5 Detail of Bayesian analysis of discovery cohorts.

a, Visualization of slices through the combined prior on effect sizes in three cohorts for mode-of-inheritance-specific models. Top row: slices through the prior effect size on Kenya (x-axis) and Malawi (y-axis) for constant effect size in The Gambia (panels). Bottom row: slices through the prior effect size on Kenya (x-axis) and The Gambia (y-axis) for constant effect size in Malawi (panels). Red lines represent a factor of 10 in the prior density. b, Comparison of BFavg (x-axis) with the minimum fixed-effect meta-analysis P value minimized across additive, dominant, recessive or heterozygote modes of inheritance (y-axis). Values are plotted on log10 and −log10 scales. Colour indicates the heterogeneity model of the model with the highest posterior weight. c, Sensitivity of BFavg to changes in prior. Plots show BFavg ratio (y-axis) plotted against one-dimensional parameterisations of the prior (x-axis), for the 32 autosomal SNPs in tier 1. Solid lines represent variants with MAF < 5% averaged across populations, and dashed lines represent variants with MAF ≥ 5%. Black dots indicate the lead marker at the FREM3/GYPE locus. Colour indicates the effect size, mode of inheritance, or heterogeneity model for the model with highest posterior weight under the GWAS prior. Dashed grey vertical lines indicate the x-axis value corresponding to the prior used in the GWAS, and one-half and twice that value. Plots are parameterized by (1) the prior standard deviation of the small-effect model keeping the prior standard deviation of the large and small-effect models in the ratio 0.75:0.2; (2–5) the prior weight on additive, dominant, recessive or heterozygote modes of inheritance; (6–10) the prior weight on fixed, correlated, independent, fixed-structured and correlated-structured models. For each parameterization prior, weights on other models are kept in the same relative proportion. For further details see Supplementary Note 4.

Extended Data Figure 6 Strongest regions of association in the Bayesian analysis of the three discovery cohorts.

Plot on left shows the log10 model-averaged Bayes Factor (BFavg). Table shows the SNP with the highest BFavg in each region (lead SNP), gene(s) of interest in the region, the model with the highest posterior weight at the lead SNP and its BF. Models are described in Methods; sml, big: small- and large-effects models; fix, cor, ind, fix-str, cor-str: fixed, correlated, independent, fixed-structured and correlated-structured effect models; add, dom, rec, het: additive, dominant, recessive, heterozygote models; fs: fixed-between-sex model. Coloured points indicate the OR and the protective allele frequency in Gambia (red), Malawi (green) and Kenya (blue). The right-hand columns indicate regions containing shared chimpanzee–human haplotypes or coding SNPs4 (ABPs), blood group genes, or immunoglobulin superfamily genes.

Extended Data Figure 7 Evidence for association in the FREM3/GYPE, INPP4B and ARL14 regions.

a, Evidence for association at directly typed SNPs. b, Posterior probability that variants in the FREM3/GYPE region are causal, assuming a single variant in the region is causal50, based on the BFavg for typed and imputed variants. Dashed lines indicate the 95% and 99% credible sets. See Fig. 1 legend for further details. c, Details of SNPs encoding the common MNS blood groups. Coordinates and alleles are with respect to the NCBI b37 human reference sequence. d, Evidence for possible independence of effects at the FREM3 and INPP4B loci in Kenya by conditional analysis. y-Axis represents −log10(association P value) conditional on the imputed dosage at rs184895969. Points are coloured by linkage disequilibrium with the top SNP rs13103597. e, Forest plot showing sample size, estimated OR and 95% CI for the lead imputed SNP (rs149373719) in INPP4B under an additive model of association. f, Bar plot showing the posterior weight on different models of heterogeneity at rs149373719 under the prior used in the GWAS, assuming an additive model of association. g, Forest plot showing evidence in both discovery and replication samples in the Sequenom data at rs77389579 in INPP4B. See Fig. 2 legend for further details.

Extended Data Figure 8 Sequence homology, alignability and structural variation in the glycophorin region.

a, Co-occurrence of short segments of DNA (k-mers; top triangle: k = 100, bottom triangle: k = 25) in the human reference sequence Each point represents a k-mer that maps to the locations indicated by the x- and y-axis positions, either on the same strand (black points) or opposite strands (red points). Green vertical lines in this and subsequent panels delineate the region of high homology surrounding the three glycophorins. b, The location of the lead GWAS marker, ABPs, and protein-coding genes in the region. c, Alignability of the 100-mer at each position of the reference, up to two mismatches. Values are taken from the UCSC genome browser mappability track and averaged over 5 kb bins. d, IMPUTE info measure in Kenya for variants with frequency at least 5%, averaged over 5 kb bins. e–g, Coverage for samples from YRI and LWK in 1000 Genomes Project Phase I carrying esv2662558, carrying esv2668125, or not carrying either deletion, respectively. Coverage for each individual is normalized by the mean coverage for that individual across chromosome 1, and only computed at positions with alignability = 1 for all 100-mers overlapping the position, and for reads with mapping quality at least 20. Values are averaged over 5 kb (grey) and 10 kb (blue) bins. Three samples with apparently erroneous calls in the 1000 Genomes Phase I genotype release are coloured (NA18519, red; NA19185, yellow; NA19222, green) and assigned to the status indicated by their coverage profile. Panel g represents a random sample of 30 individuals not carrying the deletion in addition to the two with erroneous genotype calls. Coverage computation was performed using the BAM files available from the 1000 Genomes Project in October 2014, downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data. Four African samples in the Phase I release were not assessed because they are not included in this directory.

Extended Data Figure 9 Correlation between the genotypes at SNPs of interest within the GYPE/A/B locus and reported gene transcription levels in samples from the YRI and LWK HapMap cohorts17.

P values are for a trend test of association where more than one genotype class is present. Only assays targeting the glycophorins, and those with a P value below 0.05 are shown.

Extended Data Figure 10 Detail of enrichment analysis.

a, Red histogram: the empirical distribution of the log10 distance of observed tier 1 loci to the nearest ABP haplotype. Grey histogram, distribution of distances for 10,000 simulated tier 1 sets. b, The log10 distance of tier 1 (filled red circles) and tier 2 (empty circles) loci to the nearest ABP, plotted against their rank in BFavg order (stronger signals have lower rank). Loci are annotated with the nearest gene where a gene exists within the association region. Asterisks denote nearest genes that are also the nearest gene to an ABP shared haplotype. c, Empirical null distribution of the odds ratio for the enrichment of tier 1 loci in the set of genes closest to an ABP shared haplotype, based on 10,000 simulated SNP sets. The red asterisk and text indicate the odds ratio for the observed tier 1 loci. d, Distribution of the proportion of the genome which identifies a given gene as nearest, for genes in or not in the set annotated as nearest an ABP haplotype. Left, distribution of the length of the genome for which the given gene is unambiguously the closest gene. Middle, distribution of the number of SNPs in our study for which the given gene is the closest gene. Right, distribution of the number of SNPs in our study for which the given gene is the nearest gene within a recombination interval of 2.5 cM ± 25 kb around the SNP, as used to determine nearest genes to GWAS lead SNPs. e, Empirical P values for enrichment of ABP haplotypes and coding SNPs in tier 1 and tier 2 GWAS regions. Second column, P values for enrichment by gene overlap. Third to tenth column, P values for enrichment by proximity at different length scales. †Results for simulations using SNPs frequency-matched to GWAS tier 1 loci in 1% frequency bins. ††Results for simulations excluding the regions of ABO, HBB, ATP2B4, FREM3, INPP4B, and HHIP-AS1.

Supplementary information

Supplementary information

This file contains Supplementary Notes 1-4 and additional references. (PDF 183 kb)

Supplementary Table

This file contains a summary of statistics for 32 autosomal tier 1 loci for logistic regression and linear mixed model tests. (XLSX 51 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malaria Genomic Epidemiology Network. A novel locus of resistance to severe malaria in a region of ancient balancing selection. Nature 526, 253–257 (2015). https://doi.org/10.1038/nature15390

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature15390

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing